FDA Brief

Warning letters Drugs

FDA warning letter to

sandra-pharma.is

High riskIssued Jan 28, 2021Posted Feb 2, 2021Center for Drug Evaluation and Research | CDER

FDA warned sandra-pharma.is for selling unapproved hydroxychloroquine and azithromycin online as a COVID-19 treatment.

What happened

FDA reviewed www.sandra-pharma.is on January 5, 2021, and found it offered drug products for sale to U.S. consumers with claims to treat COVID-19 and other infections. The site sold hydroxychloroquine as “Plaquinol 400mg” and azithromycin as “Azitromicina Aurovitas 500mg” together as “COVID 19 Treatment 10+3 Tabs,” saying the combination had cured COVID-19 patients and offering a protocol. FDA called the products unapproved new drugs and misbranded drugs.

What FDA found

  1. The website sells hydroxychloroquine and azithromycin for COVID-19 without FDA-approved drug applications.

    section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]
  2. The drugs are misbranded because their labeling does not bear adequate directions for safe use by a layperson.

    section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]
  3. The drugs are prescription drugs and are not exempt from the adequate-directions requirement because they are not approved in the U.S.

    21 CFR 201.115(a)
  4. Offering the drugs for sale to U.S. consumers causes misbranded drugs to be introduced into interstate commerce.

    section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
  5. The introduction or delivery for introduction of the unapproved new drugs into interstate commerce is prohibited.

    sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d), 355(a)]

What FDA wants

FDA tells the company to stop selling the unapproved and misbranded products and to email FDA’s Internet Pharmacy and COVID-19 task forces within 48 hours describing the steps taken to correct the violations and prevent recurrence, with supporting documents.

Who should pay attention

  • online pharmacies selling to U.S. consumers
  • sellers making COVID-19 treatment claims
  • prescription drug supply-chain partners

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk